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Abstract: Survival of gastrointestinal cancer remains dismal, especially for metastasized disease. For 
various cancers, especially melanoma and lung cancer, immunotherapy has been proven to confer 
survival benefits, but results for gastrointestinal cancer have been disappointing. Hence, there is 
substantial interest in exploring the usefulness of adaptive immune system education with respect 
to anti-cancer responses though vaccination. Encouragingly, even fairly non-specific approaches to 
vaccination and immune system stimulation, involving for instance influenza vaccines, have shown 
promising results, eliciting hopes that selection of specific antigens for vaccination may prove useful 
for at least a subset of gastrointestinal cancers. It is widely recognized that immune recognition and 
initiation of responses are hampered by a lack of T cell help, or by suppressive cancer-associated 
factors. In this review we will discuss the hurdles that limit efficacy of conventional cancer 
therapeutic vaccination methods (e.g., peptide vaccines, dendritic cell vaccination). In addition, we 
will outline other forms of treatment (e.g., radiotherapy, chemotherapy, oncolytic viruses) that also 
cause the release of antigens through immunogenic tumor cell death and can thus be considered 
unconventional vaccination methods (i.e., in situ vaccination). Finally, we focus on the potential 
additive value that vaccination strategies may have for improving the effect immunotherapy. 
Overall, a picture will emerge that although the field has made substantial progress, successful 
immunotherapy through the combination with cancer antigen vaccination, including that for 
gastrointestinal cancers, is still in its infancy, prompting further intensification of the research effort 
in this respect.  
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1. Introduction 
Clinical management of oncological disease of the gastrointestinal tract remains very 
challenging especially when surgical options have been exhausted. The problem gastrointestinal 
cancer poses for medicine and society at large is compounded by the nosidynamics of this group of 
diseases, for many gastrointestinal cancers showing a trend to higher incidence [1]. For advanced 
disease combinatory chemotherapy remains the mainstay of clinical management but outcomes are 
disappointing and prompt pursuit of alternative treatment modalities. Generally speaking, 
immunotherapy and especially immune checkpoint-directed therapy is now revolutionizing the 
management of oncological disease, an endeavor even awarded the Nobel prize [2]. Cancers are 
antigenic and evoke immunological responses, but can escape the resulting tumor destruction 
through a variety of mechanisms including upregulation of so-called checkpoints: inhibitory 
elements to limit self-damaging autoimmunity. By counteracting these inhibitory signals, the cancer 
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can be combatted. Such strategies have proven successful for treatment options in a range of solid 
tumors, including melanoma [3–5] and cancer of the lung [6–8]. Unfortunately, results for immune 
checkpoint inhibitors for treating gastrointestinal cancers have proven disappointing, urging 
exploration of strategies that might augment the potential of such drugs that are depending on the a 
priori presence of immune responses, as they do not initiate but enhance these [9].  
An obvious strategy to improve anti-cancer immunity apart from checkpoint inhibition is 
vaccination. Vaccinating is the act of injecting a pathogen or foreign protein with the goal to induce 
antigen specific immune responses and immunological memory. Vaccination relies on the action of 
professional antigen presenting cells (APCs) such as dendritic cells (DCs) that via presentation of 
antigens on MHC class I and MHC class II initiate CD8+ cytotoxic T cell (CTL) and CD4+ T helper 
(Th) responses, respectively. The latter are required to obtain long-lived and effective CTL responses 
[10,11].  
Because of lack of efficacy by immune checkpoint inhibitors in gastrointestinal cancers, 
vaccination is of high interest to be explored to initiate responses which can then be later on enhanced 
by add-on treatment with immune checkpoint inhibition. Design of vaccination strategies is 
complicated by the complex tumor microenvironment (TME) and other characteristics like 
mutational load and expression of tumor antigens, which are largely unique to various types of 
tumors and may vary even within tumors. This is not different for gastrointestinal cancers. 
As a consequence of the expression of embryonic or germline antigens, or because of genomic 
alterations leading to neoantigens, cancers can become immunogenic. Neoantigen load shows 
substantial variation between different forms of cancer and correlates to a certain extent with the 
success of checkpoint-directed immunotherapy [12]. Concordantly, mismatch repair deficient 
gastrointestinal (e.g., colorectal and pancreatic) cancers that bear many mutations are more 
responsive to checkpoint-directed therapies [13]. However, high neoantigen levels do not correlate 
with survival for pancreatic- and liver cancer per se [14–16]. Yet also for these cancers it is rational to 
assume that stimulating cancer-specific immune responses will be associated with better outcomes. 
However, in these situations, optimal exploitation of the available antigenic targets and combination 
therapies that overcome tumor specific suppressive mechanism are likely required.  
Nowadays we discriminate between two types of vaccination. Prophylactic (preventive) 
vaccines and therapeutic vaccines. A few examples can be given of prophylactic vaccines that are 
very effective in preventing cancer, the human papilloma virus (HPV) vaccine, preventing cervical 
cancer and the hepatitis B virus (HBV) vaccine, preventing liver cancer [17–19]. However, for 
established disease, these vaccines are also not effective because they typically induce humoral rather 
than cellular responses. In the present manuscript we shall overview the most important therapeutic 
cancer vaccine forms, elude on non-immune related cancer therapies that may trigger systemic 
immunity as a side effect, and will discuss how these therapies mechanistically offer potential for 
combination with other forms of immunotherapy to find opportunities for treatment of 
gastrointestinal cancers. 
2. The Ideal Anti-Tumor Immune Response and the Limitation of Vaccination 
A long-established cancer immune-editing theory describes the interplay between a cancer and 
the immune system, encompassing three phases: elimination, equilibrium and escape (the three E’s) 
[20]. According to this view, initially the immune system can control cancer cells (elimination), a 
process also termed immune surveillance. However, certain clones of malignant cells missed by the 
immune system (e.g., due to a non-immunogenic phenotype), escape the elimination phase 
(equilibrium). The clones that survive are then subject to immune pressure driven (epi)genetic editing, 
which ultimately leads to escape of the tumor from immune control [21,22]. In cancers these three 
phases can occur simultaneously in patients. Immune checkpoint blockade (ICB) has the potential to 
shift the balance to elimination and equilibrium. Importantly, low-fitness neoantigens may be 
leveraged by vaccination, i.e., marginal antigens in the immunosuppressive environment of a cancer 
that do not provoke effective immunity, when triggered by vaccination may confer effective anti-
cancer responses [23]. 
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Suppressive mechanisms however may limit the effect of vaccination. Tumors actively keep the 
immune system at bay by shielding themselves from the outside with a thick stroma or fibrotic shell 
[24], an anti-inflammatory microenvironment containing immune suppressive cells like M2-
macrohpages [25], regulatory T cells [26], myeloid derived suppressor cells (MDSCs) [27], or by 
utilizing immune pathways like the PD1-PDL1 axis to suppress responses [28–30]. For 
gastrointestinal cancers these anti-cancer immune suppressing mechanisms show substantial 
redundancy as in situ approaches to enhance immune system activity through local application of 
non-relevant vaccines (e.g., anti-rotaviral vaccines or anti-yellow fever vaccines) only generate local 
immune responses to cancer when combined with ICB [31,32]. Hence, overcoming the resistance to 
immune response development in gastrointestinal cancer, requires targeting multiple pathways.  
How this may be achieved is outlined in the canonical tumor immunity cycle of Chen and 
Mellman. Here, the cancer immune response is described as an ongoing cycle of tumor cell killing 
and subsequent initiation of new responses which may combat the adaptation of tumors [33]. To 
prevent tumor escape, continuous killing of tumor cells is required to trigger responses also against 
novel antigens expressed by escaping tumor cells. Vaccination may trigger an initial “therapy-
induced hit”, further releasing antigens and danger signals kick-starting the cycle. Ideally this 
therapy-induced hit should also alter the anti-inflammatory environment in the tumor to a favorable 
pro-inflammatory environment, and facilitate the influx of novel T cell clones recognizing antigens 
beyond those starting the response and thereby create a snowball effect leading to a broad T cell 
repertoire. [34,35] 
To obtain an effective immune response in cancer patients three steps are generally thought to 
be required (Figure 1): (1) Creation of the response: under certain circumstances a tumor specific CTL 
response might already exist, but in many cases, there is either no response or the response is 
ineffective. Absence of a response is likely present in immune desert tumors that encompass a minor 
but significant part of gastric, colorectal and pancreatic cancers [36]. Although for some tumors 
antigenic targets may have been largely absent (restricting vaccination opportunity), for others 
responses may have lacked because tumor specific antigens did not (yet) reach APCs/DCs or the APC 
triggered response was subsequently not properly shaped. The treatment modalities outlined in 
Table 1 and 2 mostly can support this very first step, the initiation of CTL and Th responses. Initiation 
can be achieved through conventional vaccination, with manually selected target antigens, or 
through in situ vaccination, releasing antigen via immunogenic cell death (ICD) to initiate the 
response. The latter option has the benefit that this is not limited to a set of patients expressing a 
specific selected antigen. (2) Shaping of the response, during T cell priming by APCs in the lymph 
node (LN), the costimulatory signals received by the T cells are detrimental for the efficacy of the 
eventual response. These signals are provided by DCs activated and maturated by danger signals 
and/ or by contact with activated MHC class II primed Th cells. It is pivotal for their efficacy that 
CTLs receive the correct ‘help’ signals during priming in the lymph node. The most prominent 
example is the CD28-CD80/86 axis, but other pathways like the Th supported CD40-CD40 Ligand or 
CD27-CD70 axes have also been proven essential for the ability of CTLs to migrate towards, infiltrate 
in and ultimately to kill tumors [10,11]. As such, lack of help may contribute to the immune exclusion 
phenotype which marks a large fraction of gastric, colorectal and pancreatic cancers [36]. 
Furthermore, the absence of appropriate costimulatory and help signals can contribute to the 
exhausted or dysfunctional T cell phenotype often observed in cancer [10,11,37]. These signals are 
also a point of intervention for immunotherapy. Examples are blocking antibodies for CTLA-4 
(ipilimumab; a competitive inhibitor of CD28) or agonists for CD40 that each may enhance or direct 
the shape of the response [38,39]. Combination of such drugs with vaccination could thus enhance 
the potency of the vaccine-induced response. (3) Executing the response, after the adaptive response 
has been established, fully primed and armed, T cells need to infiltrate the tumor and kill the tumor 
cells. Only then T cells will start a new cycle, tailoring immunity to the evolving cancer until the 
tumor is eradicated and memory is established, thus preventing also future growth of the tumor. 
Execution of CTL responses, however, are in many cancers, including gastrointestinal cancers, locally 
suppressed by an array of suppressive molecules and cells, such as PD1-PD-L1 or MDSCs 
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respectively [40,41]. In addition, cancer specific suppressive mechanism may prevent immune 
effector function and thus limit the effect of vaccination. Pancreatic ductal adenocarcinoma for 
example is notorious for its fibrotic immune suppressive TME that may need to be tackled (e.g., by 
focal adhesion kinase inhibitors) for immune responses to take effect [42–44]. In colorectal cancer 
aberrant WNT/β-catenin signaling shapes the TME and can render these tumors unresponsive to ICB 
and may therefore require specific attention when combined with vaccination or immunotherapy 
[45]. A suppressive TME may especially impair the effect of conventional vaccines that start the 
response outside the tumor and do not much to improve the local environment. On the other hand, 
this might be an extra opportunity for in situ vaccines, that by definition also affect the local 
environment and, by disruption of the tissue or the release of chemotactic factors, might enable 
infiltration of immune cells [46]. How do presently employed strategies relate to the above-described 
idealized scenario? 
 
Figure 1. A simple representation of an anti-tumor immune response with integration of (in situ) 
vaccination. In case of naturally arising anti-cancer immunity, antigens are released from the tumor, 
creating the response. Antigens end up in the lymph node and are presented on dendritic cells, to T 
helper cells and cytotoxic T cells. T helper cells give help signals to dendritic cells resulting in 
enhanced costimulation for cytotoxic T cells, shaping the response. Activated T cells will migrate to 
the tumor and kill the tumor cells, executing the response. However, T cells at the tumor site may 
encounter a harsh microenvironment which often starts with a physical barrier. By killing the tumor 
cells new antigens are released and the cycle can continue. In of the absence of naturally arising 
immunity, (in situ) vaccines can be used to kick start the response. 
  
Cancers 2020, 12, 1121 5 of 20 
 
Table 1. Overview of conventional cancer vaccines with pros and cons. 
Therapy Pros Cons References 
Peptide 
vaccines 
• Cheap, easy to produce 
• Long peptides: Th and CTL 
epitopes, not HLA-restricted 
• Personalized (neo-antigens) and 
semi-personalized (peptide “warehouse” 
for prevalent tumor antigens)  
• High epitope concentration 
• Short peptides: no or less Th 
epitopes cells  
• Restricted to selected 
epitopes/antigens  
• Short peptides: HLA-
restricted  





• Native sequence of protein 
• Induce humoral and cellular 
response 
• Personalized possible 
Th and CTL epitopes 
• Cheap, easy to produce 






• Contains characterized and 
uncharacterized tumor antigens 
• Th and CTL epitopes 
• Allogeneic vaccine can be given, 
broader target population 
• Poor clinical efficacy 
• Self/ normal proteins in the 
vaccine pose toxicity risk 
• Possibility of release 
immunosuppressive cytokines 
• Rejection of vaccine because 




• Measurable antigen presentation 
efficiency and DC maturation 
• Th and CTL epitopes 
• Not fully matured DCs/ 
tumor impaired DCs may induce 
tolerance 
• Logistically challenging 
• Costly, labor intensive  
[64–70] 
Table 2. Overview of in situ cancer vaccines with pros and cons. 
Therapy Pros Cons References 
Radiotherapy 
• Depending on dose, can induce 
immunogenic cell death 
• Can release uncharacterized/ 
personal tumor antigens 
• Easy to combine with immune 
checkpoint inhibitors 
• Will cause ‘late effects’ 
• Elevated risk of cancer due to 
treatment  
• Destruction of healthy tissue  
[46,71–77] 
Chemotherapy  
• Can cause immunogenic cell 
death depending on the compound 
• Can suppress specific types of 
immune suppressive cell populations 
• Easy to combine with immune 
checkpoint inhibitors 
• Will release uncharacterized/ 
personal tumor antigens 
• Overall toxicity 
• Not all chemotherapeutic 
compounds have the favored 
immunogenic effect 




• (Engineered to) Specifically 
target tumor cell 
• Can Cause immunogenic cell 
death  
• Will release uncharacterized/ 
personal tumor antigens 
• Easy to combine with immune 
checkpoint inhibitors 
• Can be engineered to express a 
tumor antigen or cytokines to modify 
the tumor micro environment 
• Anti-viral response can 
neutralizing the therapy, 
shortening the window of 
opportunity,  
• Specialized facilities to 
monitor patients due to safety 
concerns 
[32,85–92] 
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3. Conventional Vaccines 
The first cancer vaccine exploiting the immune system for cancer treatment, named ‘Provenge’ 
or “Sipuleucel-T”, was an infusion of DCs, isolated from the patient and loaded with a specific 
antigen ex-vivo [93]. Over the years many more vaccine forms/platforms have been developed 
aiming to bypass the first step in the cycle (Figure 1), to create an immunological response by offering 
the antigen in various forms, processed or unprocessed, to the patient. Various vaccine platforms 
deliver antigens in many forms and complexities ranging from tumor lysates to whole proteins, 
protein encoding mRNA, protein fragments or synthetic long peptides (SLPs) and to finally 9-11 AA 
short peptides of the minimal MHC class I binding epitope (Table 1). Although vaccines thus far have 
yielded immunological and some clinical effects, their clinical efficacy is still disappointing [64,94–
96]. The use of suboptimal vaccine platforms and of low immunogenic vaccine target antigens (e.g., 
overexpressed self-antigens) together with a suppressive tumor microenvironment is held 
responsible, as has recently been extensively reviewed elsewhere [97]. 
We will first briefly go over the main vaccine platforms and discuss their ability to create or 
shape response and to what extent they may need additional support. Because danger signals are 
crucial for the shaping of a response, conventional vaccines are often combined with adjuvants. 
Especially when low immunogenic self-antigens are targeted, such as overexpressed tumor antigens 
for which central tolerance exists, adjuvants are likely very important. The need for adjuvants and 
the type of adjuvants used may also differs per vaccine platform as will be touched upon below. We 
will, however, not discuss the various types of adjuvants in detail as there are some recent excellent 
reviews on this matter [98,99]. 
3.1. Peptide Vaccine 
Peptide vaccines exist in a short or long format, are generally stable, safe and can be used of the 
shelf for common tumor (specific) antigens or in a personalized fashion. Furthermore, peptide 
vaccines are cheap and easy to produce (Table 1). However, for personalization, genetic analysis of 
the tumor is required which may delay treatment and is not always possible to perform (for instance 
in inoperable pancreatic cancer). Short peptides (<15 amino acids (AA)) are convenient because of 
their ability to directly bind MHC, but short peptides are MHC subtype restricted and may also 
induce tolerance or on-target off- tumor toxicity by binding to MHC on non-professional APCs 
[38,51,100]. Synthetic long peptides (SLPs; ≈ 15–40 AA) in contrast, need to be processed by 
professional APCs rendering these safer and less tolerogenic and non-MHC restricted. For peptide 
vaccines obtaining sufficient MHC-epitope complexes for the creation of a response is easier than for 
whole protein-based vaccines [68]. Furthermore, SLPs can also provide MHC class II epitopes 
facilitating activation of CD4 T helper cells and have a high epitope concentration. Peptide vaccines 
may benefit from Th-skewing adjuvants, which can also be conjugated to the peptide and can further 
help shaping the response [50,101]. Combinations of peptide vaccines with forms of immune therapy 
that aid in the later stages of the response are obvious and good options, as long as sufficient T cells 
are induced and able to not only migrate to, but also infiltrate the tumor. 
In clinical practice peptide vaccines, have been and are used treat premalignant advanced or 
recurrent HPV16-induced gynecological carcinoma but also a multitude of cancers targeting cancer 
(neo)antigens [48,49]. Targeting HPV with SLPs may be of high interest also for the treatment of HPV 
related esophageal cancer [102]. Especially SLP vaccines have shown promising results with respect 
to the creation of both CTL and Th responses that also correlated with clinical effects. In premalignant 
HPV lesions more than 50% of patients showed a complete or partial response (i.e., regression of 
lesions) upon SLP vaccination [103]. In malignant disease responses were less overt. Although, 
immunological responses induced by the vaccine were observed in a majority of tested patients, no 
regression of tumors nor prevention of progressive disease was observed likely because T cell were 
impaired in the execution phase by immune suppression [104]. To lift suppression, combination of 
SLPs vaccines, with low-dose chemotherapy to kill suppressive myeloid cells, was shown to improve 
T cell responses [105,106]. Furthermore, it was found that the tumoricidal effects of PD-1 inhibition 
(with nivolumab) may be enhanced by combining it with an SLP vaccine. These encouraging results 
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were, however, obtained in a phase II single-arm study and need to be confirmed through a 
randomized control trial before changes in clinical practice are indicated [107]. Recently, also a 
personalized neoantigen-based SLP vaccine showed highly promising immunological (i.e., Th and 
CTL) and clinical responses with and without additional ICB therapy in metastatic melanoma [108]. 
In an alternative approach, recently a Phase I immunotherapy trial with two chimeric HER-2 
(commonly over-activated in gastrointestinal cancer) B-Cell long peptide vaccines were tested in 
solid tumors including gastrointestinal tumors and showed anti-tumor activity with a very 
acceptable side effect profile. This study indicates that long peptides may be even more versatile, 
triggering not only tumor directed cellular but also humoral immune responses [48]. It should prove 
very interesting to combine such approaches with immune checkpoint-directed therapy and assess 
the potential to control gastrointestinal cancer refractory to ICB monotherapy. 
3.2. Genetic vaccine 
RNA and DNA vaccines are genetic vaccines. Genetic vaccines rely on the concept that DNA or 
RNA encoding for antigens are transfected into cells and serve as a template for proteins synthesis, 
maintaining the native structure of the protein. Material from transfected cells may engage the MHC 
class I and II pathways in DCs/ APCs or DCs can be directly transfected themselves and present 
peptides on MHC I via the endogenous route of antigen presentation. Genetic vaccines may thus 
theoretically induce humoral and both CD8 cytotoxic T cell responses and CD4 T helper cell 
responses although the extent of each may vary depending on the dominant target cell of a specific 
genetic vaccine. [55,109] Genetic vaccines are relatively cheap and simple to synthesize. They are safe 
and highly flexible and a broad range of antigenic targets can be selected with this technique. 
However, genetic vaccines may be limited in immunogenicity and the antigen levels obtained are 
more variable and harder to control than for peptide vaccines. Yet, the genetic vaccine has come a 
long way with many optimizations in, e.g., codon optimization, novel plasmid vectors, vector 
boosting regimens and more. [56] Although genetic vaccines have intrinsic adjuvant properties by 
binding to pattern recognition molecules recognizing nucleic acids, this may not necessarily aid their 
effect as it induces and antiviral state, abolishing antigen translation [109]. Rather, for optimal efficacy 
an adjuvant effect may need to be pursued after genetic vaccine induced antigen production. This 
can be achieved for example by co-expression of immune activating proteins (e.g., CD40L, CD70) or 
cytokines (e.g., IL12) [109]. Alternatively, potential for combination with other forms of immune 
therapy might also lie in the priming and shaping phase. For example, therapeutic compounds 
targeting the APCs for enhanced immunogenicity like CD40 agonists or other T cell activators in 
clinical development to aid in the shaping of the response.  
DNA vaccination has been clinically tested in HPV related neoplasia and a multitude of cancers. 
On precancerous HPV lesions the vaccine had beneficial effects causing histopathological regression 
in a significant number of patients. [110] However, clinical trials with DNA vaccines in more 
established diseases like melanoma, prostate-, colorectal- or breast cancer disappointed in terms of 
therapeutic outcome, despite the immunological responses induced. [53,54,57,111–117] Yet, these 
results pave the way for combinations with therapies to lift the suppressive mechanisms of the tumor. 
Additionally, mRNA vaccines have been applied to many different cancers and have shown 
immunogenicity and some clinical responses [109]. Of special interest is a recent clinical study on the 
vaccination of 13 late stage melanoma patients with mRNA encoding mutated parts of proteins 
(27AA with the mutation in the middle; 10 potential immunogenic mutations per patient) that 
resulted in T cell responses against multiple neo-epitopes in all patients (mostly Th but also CTL). 
Despite low patients numbers this study also showed promising clinical effects including a complete 
response in one patient receiving the vaccine combined with PD-1 blockade [118]. 
For many approaches, antigen selection remains a bottleneck. The most obvious way to address 
this is combining genetic analysis of the cancer and patient HLA phenotype with prediction tools that 
identify promising candidates. Now that many centers are building molecular precision medicine 
pipelines for drug selection in gastrointestinal cancer, it is also becoming feasible to use the 
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infrastructure for selecting epitopes suitable for personalized genetic vaccines, which in combination 
with ICB therapy may prove exceedingly useful.  
3.3. Tumor Cell Vaccine 
Tumor cell vaccines are whole-cell vaccines consisting of inactivated allogeneic tumor cell lines 
or of autologous tumor cells. They contain characterized, but also uncharacterized, tumor antigens 
which lie at the basis of inducing the immune response. Examples are Canvaxin and GVAX [119]. 
GVAX is a tumor cell vaccine where the origin of tumor cells can be autologous or allogeneic (can be 
given to a broader target population). Because the vaccine consists of ‘whole protein’, it will contain 
Th and CTL epitopes. In GVAX, the tumor cells are engineered to express granulocyte macrophage 
colony stimulating factor (GM-CSF). In mice genetically modified tumor cells engineered to express 
cytokines like interleukin 2 (IL-2), interferon gamma (IFN-y) or GM-CSF can be rejected and can 
induce systemic immunity. Subsequent characterizations of the induced immune response revealed 
a local influx of immature dividing monocytes, granulocytes and activated lymphocytes at the 
injection site. Moreover, paracortal hyperplasia was observed at the draining lymph node. Most of 
this preclinical work was done in mouse models of melanoma but was also extended to renal cell 
carcinoma, colon carcinoma and fibrosarcoma models. [119,120] 
Although these preclinical results were promising, the clinical efficacy of GVAX was thus far 
limited. Studies have mostly been performed in (but not limited to) prostate cancer, pancreatic cancer 
and colorectal cancer [58,60,61,121]. Immunologically, Th cells have been demonstrated to be induced 
upon treatment with GVAX, however, these studies often included combination of GVAX with 
checkpoint inhibitors like ipilimumab [60]. This complicates our understanding of the sole effect of 
GVAX on the adaptive immune response. Additionally, due to allogeneic HLA, the vaccine might be 
rejected and may not induce an effective anti-tumor immune response. GVAX-ICB combinations are 
currently pursued further in the clinic. [58] Interestingly, one of the biomarkers that was found 
associated with survival in pancreatic cancer following GVAX combined with ipilimumab was a 
diversification of the T cell receptor (TCR) repertoire [58,121]. Although ipilimumab has this effect 
already by itself, diversification was most clear upon co-treatment with GVAX [58,61,121]. 
3.4. DC-Vaccine 
Dendritic cells are considered the most important professional APC crucial for the initiation of 
any adaptive response [122]. They are very efficient in the phagocytosis of antigens, and subsequently 
process these and load derived peptides on MHC class II. In addition, DCs excel in the cross 
presentation of incoming antigens on MHC class I to T cells. DCs also provide the necessary 
costimulation to T cells for proper activation and function. Finally, they can secrete cytokines that 
further shape T cell function. In vivo different DC subtypes can be discriminated (i.e., myeloid DC1, 
DC2, plasmacytoid DC and inflammatory monocyte derived DC) that differ in function [123]. Of 
particular interest are the rare subset of DC1 that are thought to excel in cross presentation and in 
mice have been demonstrated to be crucial to the activation of naïve T cells and are thought to transfer 
help signals to CD8 cytotoxic T cells through CD4 T helper cells [124–126]. DCs can be loaded with 
antigens and activated ex-vivo and be given to a patient as a therapy [15,62,63,127–129]. For loading 
of vaccine DCs all the aforementioned forms of antigens can be used (i.e., short and long peptides, 
DNA, RNA and tumor lysates). For DC vaccination monocyte derived DCs (moDCs) have been 
popular because they can be easily differentiated ex-vivo from monocytes that can be obtained in 
large numbers through leukapheresis. Current thought is, however, that moDCs are not the most 
optimal DC for vaccination [66,130]. Primary DC subsets, which can only be harvested in lower 
numbers from patients, may be more effective and have recently also been used for vaccination with 
promising results. The DC type used, the antigen loaded and the activation method used together 
likely greatly determine the ability of the DC to create and shape a response. Efforts are currently 
directed at the exploitation of primary DC subsets including rare DC1 for vaccination and at 
optimizing DC loading and activation [130]. 
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Although DC vaccination is time and resource consuming, antigen loading and DC activation 
can be well controlled and monitored which is less for other cancer vaccine platforms. DC therapy 
has been proven to be safe in the clinic and preliminary data deems it efficacious, triggering both Th 
and CTL responses and also yielding some clinical responses [66]. Currently DC vaccines are tested 
in several advanced phase II/III trials including gastrointestinal cancers [69]. For DC therapy, 
however, use as a stand-alone therapy has thus far been disappointing despite their proven ability to 
trigger T cells [67]. DC vaccines very likely require support of T cells in the execution phase for clinical 
effect. Concordantly, many trials with combinations of DC vaccines with checkpoint inhibitors like 
PD-1/ PD-L1 and CTLA-4 inhibitors are ongoing [65,69,131]. 
4. In Situ Vaccines 
Besides these conventional vaccination strategies, there are also several other therapies that can 
have an in situ vaccine effect which initial purpose was not to generate immunological memory or 
an immune response at all [71,132,133]. These treatment modalities can cause the release of antigen 
and thereby can have a vaccine-effect in situ, resulting in the induction of an immune response and 
the development of immunological memory [134]. Their strongest edge over most conventional 
vaccines is that screening of the patient for antigen-positivity is not needed [72,85,135–137]. For these 
in situ vaccines the effectiveness of the resulting immune response depends on the expression of 
immunogenic antigens in the tumor at the time of treatment. The response will by definition be 
‘personalized’, and the lack of need to screen for tumor antigen expression may save valuable time. 
Furthermore, in case of local treatment and induction of a systemic immune response, also metastasis 
might be targeted indirectly due to the partial antigenic similarity of the main tumor and the 
metastasized tumors (i.e., an abscopal effect) [73]. An overview of the most important therapies with 
a known in situ vaccination effect is given in Table 2.  
The concept of in situ vaccination comprises that the antigens causing the vaccine effect are 
already present in the tissue and are released upon therapy. Upon release these antigens are taken 
up by phagocytic cells and transported to the lymph node for the induction of specific, personalized 
adaptive immune responses [86]. In situ vaccination is thus an attractive form of personalized 
medicine as any tumor will have its own profile of tumor antigens and mutations that might form 
neoantigens (i.e., new antigens to be loaded on HLA-molecules). For treatments having an in situ 
vaccine effect, tumors do not necessarily have to be characterized before starting treatment, saving 
valuable time. Possible limitations of the in situ vaccination however, might be that antigens might 
not be present in such a concentration to allow effective antigen (cross)presentation and the creation 
of proper responses. Furthermore, as the antigens carrying the vaccine effect are not known it is 
difficult to monitor the response [74]. Lastly, antigen release following these treatments might not 
always be accompanied by sufficient danger signals to shape the response (and break tolerance in 
case of self-antigens). Especially in this scenario, responses following the in situ vaccination may 
benefit from immunotherapeutic agents that are designed to stimulate/initiate key mechanisms 
important to the shape and execution of an effective adaptive immune response [135,137]. Although 
many conventional cancer therapies used to treat gastrointestinal cancers may have an in situ vaccine 
effect, we will restrict our discussion to those most widespread used.  
4.1. Radiotherapy 
Radiotherapy is still one of the most important treatment modalities for cancer and is also 
standard-of-care or at least a treatment option for many gastrointestinal cancers [138]. It causes 
radiation-induced cell death trough lethal DNA damage [139]. A secondary effect of radiotherapy is 
activation of the immune system as it leads to ICD of the tumor cells by ionizing radiation [81]. 
However, complications might arise due to destruction of not only cancerous tissue but also healthy 
tissue, inducing so called ‘late-effects’ that might even lead to an increased risk of getting cancer in a 
later stage of life due to the radiation.  
Radiotherapy not only releases antigens for uptake by APCs but may also provide cell death-
associated danger signals (e.g., cell surface calreticulin, ATP, nucleic acids, HMGB1) important for 
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DC activation and immune cell recruitment [140]. Thus, radiotherapy may be effective to create and 
shape the response. Apart from the activation of the immune system, effects of ionizing radiation are 
also seen in the tumor microenvironment for example on the vascular endothelium where factors 
involved in the recruitment of T cells were increased following radiotherapy [76,77,141–143]. It is 
important to note, however, that not every radiation dose has the same effect. In mice, the release of 
cell free DNA in the tumor was found to be compromised by the expression of DNA exonuclease 
following a single high radiation dose. This was thought to prevent the activation of the cGas-STING 
pathway and therefore prohibited immune cell activation. In this same study combination of 
radiotherapy with a CTLA-4 inhibitor, provides not only a local immune stimulatory effect but also 
an abscopal effect by the generation of systemic immunity [144]. Furthermore, in a mouse model of 
pancreatic cancer the induction of tumor specific memory cells by radiotherapy was enhanced by 
combination with a CD40 agonist [145]. 
One of the concerns of combining radiotherapy, as the inducer of the immune response, and 
ICB, removing the brakes from the immune response, is safety, especially as also self-antigens are 
released. Checkpoint inhibitors are known to have side effects, and when combined with each other, 
these might occur significantly more [146]. Combining radiotherapy with ICB, however, has thus far 
been reported to be safe and well tolerated [147–149]. 
In mice, anti-CTLA4 treatment predominantly inhibited regulatory T cells while radiation 
therapy enhanced the TCR repertoire of intratumoral T cells. When these therapies were combined, 
anti-CTLA4 promoted the expansion of T cells and radiation shaped the TCR repertoire of the 
expanded peripheral clones, thus these modalities synergized to create the response as well as to 
shape the response [149]. However, in patients this combination was less effective. Melanoma 
patients showing high PD-L1 expression in the tumor, when treated with ionizing radiation together 
with anti-CTLA4, developed T cells with an exhausted phenotype and the tumors progressed [149]. 
In lung cancer a case of clinical success of combination of RT with CTLA-4 was reported [150] and 
also combination with PD-1 blockade showed promising results [151]. In mice it was shown that in 
addition to ionizing radiation and anti-CTLA4, supplemented with PD-L1 blockade reversed T-cell 
exhaustion and aided in the execution of the response suggesting further combination of 
radiotherapy with multiple checkpoint inhibitors could be more effective [147–149] Although the 
combination with radiotherapy may be superior to just ICB, not all inhibitors have the same efficacy 
and are based on different mechanisms. More mechanistic insight is now required to make good 
combinations—optimally covering all three requirements depicted in Figure 1 [140]. 
4.2. Chemotherapy 
Chemotherapy is extremely versatile and apart from stopping tumor proliferation directly it 
may also aid the generation of anti-tumor immunity. In general, it is used as a therapy to manage 
disease and treat lower grade cancers. [152] However, chemotherapy also holds potential to enable 
other therapies to become more efficacious in late stage cancer. Immunological effects of 
chemotherapy can be induction of ICD, releasing both danger signals and tumor antigens facilitating 
antigen presentation, induction of a cellular senescence program in tumor cells that alert the immune 
system by activation of natural killer (NK) cells and finally the inhibition of immune suppressive cell 
populations like regulatory T cells or myeloid derived suppressor cells (MDSCs). [78,82,83] Most 
important chemotherapeutics that lead to ICD are idarubicin, epirubicin, doxorubicin, mitoxantrone, 
oxaliplatin, bortezomib and cyclophosphamide [153]. These individual chemotherapeutic agents 
have been extensively discussed for their specific immune modulatory properties elsewhere [153–
155]. It is important to note that the immunological effects of chemotherapeutic drugs might vary 
greatly. This is illustrated by differential ICD in response to the related chemotherapeutics cisplatin 
(no ICD) and oxaliplatin (ICD), both commonly used to treat gastrointestinal cancers [153,156]. Thus, 
not all chemotherapeutics may benefit similarly from a combination with immunotherapy.  
In general, combination of chemotherapy with checkpoint inhibitors (anti-CTLA4 or anti-PD-
(L)1) is well tolerated. In various types of cancer like lung cancer and biliary tract cancer, the 
combination also seems to be superior compared to single immunotherapy or chemotherapy alone. 
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[157–160]. Additionally, for pancreatic cancer the combination of gemcitabine chemotherapy with 
PD1 was well tolerated and holds promise [161].  
Although combination of ICB with chemotherapy occurs very often in clinical trials, this is most 
often because it was a standard of care treatment for these patients rather than a rational choice based 
on the immunological effects of specific chemotherapeutic agents. However, there are several 
exceptions that are explicitly meant to exploit the immune stimulating actions of ICD-inducing 
chemotherapeutics [153,162]. One of these is a recent multi-arm phase II study comparing the 
combination of various ICD and non-ICD inducing chemotherapeutics with PD-1 inhibitor 
nivolumab [163]. Results confirmed the superiority of combining ICB with ICD-inducing 
chemotherapy (in this case doxorubicin). 
4.3. Oncolytic Viruses 
Oncolytic viruses (OV) have been discovered by accident in patients from cases that experienced 
tumor reduction after contracting a natural viral infection [91,92]. OV based on naturally replicating 
viruses are selective for tumor cells in particular. These viruses exploit the fact that tumor cells, in 
order to attain features beneficial for uncontrolled growth, trade in some basic biological processes, 
one if which is the innate response mechanism to viral infection. Because this is lacking in tumor cells, 
oncolytic viruses can specifically infect the tumor and cause cell death. Although various viruses 
have been tested for this purpose, of particular interest are two recent studies in mice, demonstrating 
oncolytic effects after intratumoral vaccination with common prophylactic vaccines based on 
attenuated viruses (i.e., yellow fever and rotavirus) [31,32]. Another class of oncolytic viruses is 
formed by viruses genetically modified to target and kill a tumor [92]. Although it was thought that 
direct cell killing by the virus was responsible for tumor control/regression, evidence is accumulating 
that systemic immunity that can originate from this killing (an in situ vaccine affect) is also very 
important. Like radiotherapy and chemotherapy, OVs can cause ICD, releasing antigen and promote 
a local pro-inflammatory environment, leading to an adaptive immune response [89]. Additionally, 
recombinant OVs are being tested in the clinic carrying various tumor antigens, using the OV 
simultaneously as a viral vector [87]. In comparison to radiotherapy and chemotherapy, the 
experience with the combination of oncolytic viruses and ICB is still in its infancy [31,92]. Clinical 
trials combining several different form of OVs (including recombinant OVs carrying various types of 
antigen) with PD1/PD-L1-, CTLA-4 inhibitors or other forms of immunotherapy are currently 
ongoing [164]. Pioneering clinical results have been obtained in melanoma where response rates with 
a genetically modified GM-CSF expressing herpes simplex based OV (T-VEC) in the presence of 
CTLA-4 or PD-1 blockade were promising and even improved in patients treated with OV 
combination therapy compared to anti-CTLA4 alone [90,165,166].  
5. Conclusions 
To obtain the best therapy combination of immune stimulatory approaches that create and shape 
an effective adaptive anti-tumor response and also support this response optimally in the execution 
phase, it is important to characterize the immune status of a patient (-population) [167]. In case of 
evidence of an ongoing active immune response, ICB can be considered as a stand-alone treatment. 
However, in most cases there is no proper adaptive immune response against the tumor. Vaccination 
offers the possibility to create a response, inducing T cells, but especially for gastrointestinal cancers 
additional support of the response through checkpoint inhibitors may prove essential. There are 
many forms of vaccination and therapies with an in situ vaccine effect, as were discussed in this 
review. Therapies with in situ vaccination effects provide considerable opportunities, as they do not 
depend on the characterization of tumor antigens or vaccine design/ manufacturing and may also 
disrupt the TME which greatly limits immune resolution of many gastrointestinal cancers. Novel 
therapies like OVs are of high interest but also more common therapies like radiotherapy and 
chemotherapy that are already part of routine clinical practice may prove exceedingly useful in this 
respect. To find more effective therapies for ICB resistant gastrointestinal cancers, it seems 
worthwhile to evaluate and investigate immunological effects of non-immune standard-of-care 
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treatments. A direction might be to identify and investigate intrinsic features of gastrointestinal 
cancers like composition of the TME. A tumor devoid of T cells, or populated with mainly exhausted 
terminally differentiated non-responding T cells might be in need of a new immune response cycle. 
Such tumors are ideal candidates for (in situ) vaccination. For tumors with a low mutational load 
targeted therapies like peptide vaccines could be utilized to induce or enhance CTL responses. 
However, with a higher mutational load and/or higher immunogenic antigen presentation 
radiotherapy or chemotherapy may be the preferred way to get that initial release of antigens.  
However, immune regulatory mechanisms may still be in place that will prevent antitumor 
immunity. Identifying these mechanisms in a personalized manner can aid in the selection of immune 
checkpoint inhibitors (or alternative therapies) to combine with vaccines to give that last push to shift 
the equilibrium to tumor cell killing and promote remission in patients. For example, a patient 
harboring only little or dysfunctional/helpless CTLs could be treated with a vaccine and subsequently 
with PD(L)1 inhibition to rescue effector function at the tumor site.  
To make effective combinations we now need more detailed insight into the power and 
mechanism of each (in situ) vaccine form to create and shape the response and also more knowledge 
on the timing of the created response. Furthermore, we need to know what essential properties 
induced T cells may lack, so specific signals or blockages can be provided to fix these shortcomings. 
[168] Only then can we provide the best combination immunotherapy at the right moment. In the 
near future the repertoire of checkpoint inhibitor options will expand. Many new forms of such 
therapy are currently in clinical development including blockade of LAG3, TIGIT, IDO, CD47, or 
TIM3, especially the latter may be of particular interest to combine with treatments causing ICD as it 
is a receptor for HMGB1 keeping this compound and associated DNA from triggering TLRs [169,170]. 
Additionally, several immune stimulators are currently clinically evaluated and may be used to 
enhance the shaping of adaptive responses following (in situ) vaccination (e.g., activators of OX40, 
GITR) [169]. Moreover, for combinations of (in situ) vaccine forms with these compounds we need 
more insight into the level at which vaccine-induced responses require support. Especially for in situ 
vaccines this may be challenging, as the nature of the antigens driving the vaccine effect is not known. 
State of the art analysis techniques may give answers. For example, immune responses in these 
patients could be followed by non-invasive tests like a screening for the TCR repertoire diversity in 
blood before and after initial therapy and by subsequently tracing back the phenotype of cells 
carrying prevalent TCR using single cell sequencing. [171] By verifying induction of an immune 
response after a first ‘therapeutic hit’, as described in Figure 1 (create the response), this can be 
followed-up by treatment modalities that support the effector cells and aid in executing the response, 
potentially leading to a superior treatment strategy against cancers in general and gastrointestinal 
cancers in particular. 
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